Curated News
By: NewsRamp Editorial Staff
April 24, 2025
Quantum BioPharma Appoints Kevin Malone as Advisor to Board of Directors
TLDR
- Kevin Malone, a seasoned financial advisor, joins Quantum BioPharma as advisor, enhancing market insights and shareholder protection.
- Quantum BioPharma appoints Kevin Malone, known for market pattern recognition, as advisor to Board of Directors, aligning with shareholder protection.
- Quantum BioPharma's appointment of Kevin Malone promotes financial literacy, advocating against trading manipulation for shareholder protection and therapeutic focus.
- Kevin Malone, renowned financial advisor, advocates against naked short selling, aligning with Quantum BioPharma's values and focus on shareholder protection.
Impact - Why it Matters
This news highlights the strategic move by Quantum BioPharma to enhance its leadership team with expertise in financial markets. Malone's appointment signifies a commitment to shareholder protection and therapeutic advancements, positioning the company for future growth and innovation.
Summary
Quantum BioPharma (NASDAQ: QNTM) appoints Kevin Malone as an advisor to its Board of Directors, known for his financial expertise and advocacy against trading manipulation. Malone's mission aligns with Quantum's shareholder protection values and therapeutic focus.
Quantum BioPharma is a biopharmaceutical company focused on innovative solutions for challenging disorders. Through its subsidiary, Lucid Psycheceuticals, it is developing Lucid-MS to treat multiple sclerosis. Quantum BioPharma also invented UNBUZZD and retains ownership of Celly Nutrition Corp.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Appoints Kevin Malone as Advisor to Board of Directors
